Stock Research for GSK

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

GSK Stock Chart & Research Data

The GSK chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GSK chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


GSK Due diligence Resources & Stock Charts

The GSK stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View GSK Detailed Price Forecast - CNN Money CNN View GSK Detailed Summary - Google Finance
Yahoo View GSK Detailed Summary - Yahoo! Finance Zacks View GSK Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View GSK Trends & Analysis - Trade-Ideas Barrons View GSK Major Holders - Barrons
NASDAQ View GSK Call Transcripts - NASDAQ Seeking View GSK Breaking News & Analysis - Seeking Alpha
Spotlight View GSK Annual Report - CompanySpotlight.com OTC Report View GSK OTC Short Report - OTCShortReport.com
TradeKing View GSK Fundamentals - TradeKing Charts View GSK SEC Filings - Bar Chart
WSJ View Historical Prices for GSK - The WSJ Morningstar View Performance/Total Return for GSK - Morningstar
MarketWatch View the Analyst Estimates for GSK - MarketWatch CNBC View the Earnings History for GSK - CNBC
StockMarketWatch View the GSK Earnings - StockMarketWatch MacroAxis View GSK Buy or Sell Recommendations - MacroAxis
Bullish View the GSK Bullish Patterns - American Bulls Short Pains View GSK Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View GSK Stock Mentions - StockTwits PennyStocks View GSK Stock Mentions - PennyStockTweets
Twitter View GSK Stock Mentions - Twitter Invest Hub View GSK Investment Forum News - Investor Hub
Yahoo View GSK Stock Mentions - Yahoo! Message Board Seeking Alpha View GSK Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for GSK - SECform4.com Insider Cow View Insider Transactions for GSK - Insider Cow
CNBC View GSK Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for GSK - OTC Markets
Yahoo View Insider Transactions for GSK - Yahoo! Finance NASDAQ View Institutional Holdings for GSK - NASDAQ


Stock Charts

FinViz View GSK Stock Insight & Charts - FinViz.com StockCharts View GSK Investment Charts - StockCharts.com
BarChart View GSK Stock Overview & Charts - BarChart Trading View View GSK User Generated Charts - Trading View


Latest Financial News for GSK

Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI
Posted on Friday June 22, 2018

Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.


Mylan Stock Looks Cheap, but Don’t Overlook These Risks
Posted on Thursday June 21, 2018

Mylan N.V. (NASDAQ:MYL) has been a battleground stock in 2018. EpiPen is a perfect example. The brand brought Mylan shame and a substantial fine, but it’s also in short supply now, continuing to lead to strong ongoing profits.


Glaxo Venture's Lofty Goal in HIV: Eclipse Gilead as Top Player
Posted on Wednesday June 20, 2018

GlaxoSmithKline Plc’s HIV venture wants to use less burdensome forms of treatment to unseat rival Gilead Sciences Inc. and become the top player in the $26 billion-a-year market in the mid-2020s. “If our pipeline and our competitors’ pipelines play out as we’re expecting, that’s our aim,” Deborah Waterhouse, chief executive officer of ViiV Healthcare, told journalists at a briefing Wednesday in London. Glaxo and partner Pfizer Inc. are taking on Gilead with a strategy to develop two-drug HIV combinations rather than the three-drug regimens that have been the standard for many years.


GSK takes billion-dollar drug fight with Gilead to top AIDS meeting
Posted on Wednesday June 20, 2018

GlaxoSmithKline (GSK.L) is taking its fight with Gilead Sciences (GILD.O) for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment. The drugmakers are touting rival strategies for fighting the AIDS virus, with GSK betting that a shift to using two drugs rather than the standard three will boost its market share, while Gilead sticks with the tried and tested triple approach. Deborah Waterhouse, head of GSK's majority-owned HIV business ViiV Healthcare, aims to overtake Gilead as market leader in the $26 billion-a-year (19.8 billion pounds) HIV market by the mid-2020s, assuming the gamble on two-drug combinations pans out.


Enter a stock symbol to view the stock details.